The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer
- 18 March 2005
- Vol. 23 (17-18) , 2374-2378
- https://doi.org/10.1016/j.vaccine.2005.01.014
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: